A 15-year-old female with a history of hypothyroidism presented with severe anemia and thrombocytopenia in the setting of prolonged menses. After further evaluation, she was diagnosed with pseudohypoparathyroidism Ia (PHPIa). Her symptoms improved after starting medications and receiving a platelet transfusion, but a few weeks later she returned with complaints of bleeding and dizziness and was found to be thrombocytopenic once again. Her platelet counts improved after administration of intravenous immunoglobulin (IVIG), leading us to believe she has combined immune-mediated platelet destruction in addition to platelet dysfunction associated with her PHPIa.

Background: Thyroid dysfunction is common especially in women over the age of 50 years. The prevalence of thyroid abnormalities is more in postmenopausal women using hormone replacement therapy. The prevalence of biochemical (or subclinical) hypothyroidism in women increases steadily with age, rising from 10% to 20% in the postmenopausal. The study results clearly indicate an increase in the activities of TSH among the older-aged post-menopausal women. Objective: To compare the sonographic findings of thyroid gland in post-menopausal women with and without hormone replacement therapy. Material and Method: A review of scientific literature concerning the correlation of Sonographic abnormalities of thyroid gland in post-menopausal women with and without hormone replacement therapy was done. Different platforms including medical journals, books and online resources(e.g., PubMed, Google Scholar & Medline) were explored to find the relevant data using the mesh Terms: Thyroid gland, postmenopausal women, Hormone Replacement Therapy etc. The main focus was given to the latest data published in the last 10 years.

Background: Thyroid dysfunction is common especially in women over the age of 50 years. The prevalence of thyroid abnormalities is more in postmenopausal women using hormone replacement therapy. The prevalence of biochemical (or subclinical) hypothyroidism in women increases steadily with age, rising from 10% to 20% in the postmenopausal. The study results clearly indicate an increase in the activities of TSH among the older-aged post-menopausal women. Objective: To compare the sonographic findings of thyroid gland in post-menopausal women with and without hormone replacement therapy. Material and Method: A review of scientific literature concerning the correlation of Sonographic abnormalities of thyroid gland in post-menopausal women with and without hormone replacement therapy was done. Different platforms including medical journals, books and online resources(e.g., PubMed, Google Scholar & Medline) were explored to find the relevant data using the mesh Terms: Thyroid gland, postmenopausal women, Hormone Replacement Therapy etc. The main focus was given to the latest data published in the last 10 years.

Coronavirus disease 2019 (COVID-19) started as an epidemic in Wuhan in 2019 and was declared pandemic by WHO in March 2020. The virus has been identified and named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This novel coronavirus strain is the causative agent of COVID-19, and continues to rapidly spread worldwide. SARS-CoV-2 is a highly pathogenic and transmissible coronavirus that spreads through respiratory droplets and unprotected close contact. “COVID-19 outbreak, which has caused >95 million confirmed infections and >2 million coronavirus related deaths, is one of the most disastrous worldwide crises in recent years. Several methods have been used to examine SARS-CoV-2 infections.” i.e. RT-qPCR for viral RNA detection, and rapid screening procedures for antibody or virus detection. COVID-19 shows an incubation period of 3–7?days globally. Approximately 80% of the cases remain mild or asymptomatic, 15% are severe and 5% infectious cases turn to critical, requiring ventilation [2]. Several clinical trials have been proposed for its treatment and management with supportive aim of mortality reduction [1]. By glancing a view on fig 1, it can be evidently seen that COVID-19 cases have started to rise significantly since last few months. Furthermore, as per World Health Organization (WHO), there have been 131,020,967 confirmed cases of COVID-19 at a global level recently.

Aim: To evaluate the therapeutic and evolutionary aspects of diabetic ketosis decompensation, a decade after its previous report in our center. Materials and Method: This was a 3-year retrospective study, including all patients admitted from June 1, 2016 to May 31, 2019 for DKA at the Endocrinology and Metabolic Diseases Department of the National and University Hospital Hubert Koutoukou Maga (CNHU-HKM). Ketosis was defined by the presence of at least 2 acetone crosses on the urine strip. Results: A total of 196 patients were included. The mean age was 43.73 years ± 16.2 years with a sex ratio of 0.96. The prevalence of DKA was 28.99%. The main precipitating factors of DKA were infections (67.86%) and non-compliance to the treatment (29.59%). The most common infections were urogenital (23.30%), respiratory (18.04%) and malaria (32.33%). The mortality was 2.55%. Male subjects (84.36%) had blood glucose levels above 3g/L with a higher mean dose of insulin used (84.71 IU versus 54.29 IU for women p=0.008). Duration of recovery (p=0.008) and length of hospitalization (p=0.006) were statistically longer for men. Conclusion: The prevalence of ketosis decompensations remains high. The main decompensation factors found were infections and non-compliance to treatment. Improving patient care over the past decade had produced a positive impact on mortality, recovery time and length of hospitalization.

The accelerated ageing that occurs in diabetes results in earlier appearance of the geriatric phenotype, including frailty. Recent guidelines have stressed the need for assessing frailty in the evaluation of older adults living with diabetes. Once evaluated and identified, however, the presence of frailty marks a significant change for the individual. Treatments that have been continued and encouraged often for many years, may be discontinued. Life-prolonging medications such GLP-1 analogues, and SGLT-2 inhibitors are replaced with therapies designed to improve quality of life, reduce glycaemic variability and stabilise the sarcopaenia that characterises frailty, such as insulin. With this, however, comes new problems, such as the risk of hypoglycaemia, the need to for capillary glucose monitoring and sub cutaneous administration. Additionally, new diagnoses that are more common in people in diabetes, such as stroke, heart disease, dementia, falls and fractures will result in further changes, with the need for care and possibly even institutionalisation.